Will the FDA approve MDMA for PTSD?
Oct 20, 2028even chance by
- Before Jan 1, 202710%
- Before Jan 1, 202842%▲ 8
- Before Jan 1, 202952%▲ 1
3 more
- Before Jan 1, 203053%▲ 1
- Before Jan 1, 203153%▲ 1
- Before Jan 1, 203253%
Install
FDA decision: BBP-418 by Ml Bio Solutions Inc. (in 2026)
The odds
92%chance
How the odds have moved
Yes: 92% on Oct 19, 92% now.
Each outcome's chance over time on Kalshi. The dots along the bottom are headlines about its subject: point at one to read it.
Every outcome
| Outcome | Chance | Day | Bid | Ask | Pays | Contracts |
|---|---|---|---|---|---|---|
| Yes | 92% | 88¢ | 95¢ | $1.05 | 854 |
"Pays" is what a $1 stake returns if that outcome happens, at the price shown (before any fees). Bid and ask are the best prices to sell and buy "Yes".
The news: FDA, Ml Bio Solutions Inc
Search ›-
FDA has finalized its guidance on apps related to drugsSTAT is a media company focused on finding and telling compelling stories about health, medicine, and scientific discovery. We produce daily news, investigative articles, and narrative projects in addition to multimedia features, podcasts… -
FDA to pull common but ineffective cold medicine from marketNovember 7, 2024 / 12:32 PM EST / CBS News The Food and Drug Administration announced Wednesday that it would seek to pull a widely used ingredient in cough and cold medicines from the market, after the agency's scientists concluded that… -
Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addictionSTAT Telehealth leapfrogs FDA approval with off-label GLP-1 prescriptions for addiction Online platforms, experts say, can shift the burden of vetting unapproved drugs on to patients Katie covers the impact of health technology on… -
Nasal decongestant phenylephrine, found in many over-the-counter cold and allergy medicines, doesn't work, FDA experts sayUpdated on: September 16, 2023 / 8:59 PM EDT / AP The leading decongestant used by millions of Americans looking for relief from a stuffy nose is likely no better than a dummy pill, according to government experts who reviewed the latest… -
Is my GLP-1 safe? What to know about FDA's crackdown on copycat drugsCheaper copycat versions of the popular weight-loss drugs Wegovy and Zepbound are still being marketed to consumers. The thriving market for "compounded" GLP-1 medications persists despite warnings from federal drug regulators, a recall… -
A bipartisan group of lawmakers urges the FDA to close a peptide loopholeA Theranos whistleblower watched all three hours of “You Can See Everything,” so you don’t have to. Send news tips and boring truths about liars to [email protected] or John_Wilkerson.07 on Signal. Elevance Health holds its third-quarter… -
FDA allowing food companies to switch to salt substituteCBS News FDA allowing food companies to switch to salt substitute Chicago still accepting submissions for official 2026 Christmas tree Metra UP-NW train hits vehicle in Des Plaines, delays service Expert weighs in after nearly 1,000 birds… -
FDA Issues Final Guidance on Mandatory Recallshappi Stream offers a centralized destination where users can watch expert-led sessions anytime, anywhere. “No substantive changes” from the draft guidance issued in December 2025, according to the Agency. After reviewing public comments… -
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar AtaxiaThe FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter. The FDA has accepted the resubmitted new drug application (NDA) for troriluzole… -
FDA Finalizes NDIN Identity and Safety GuidanceOn October 19, 2026, FDA released a final guidance document titled “New Dietary Ingredient (NDI) Notifications and Related Issues; Identity and Safety Informa - On October 19, 2026, FDA released a final guidance document titled “New… -
FDA approves new tricuspid valve repair systemEdwards Lifesciences announced that the FDA approved its system for tricuspid valve repair. The repair system (PASCAL Precision) is indicated for patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy at… -
Onvansertib Receives FDA Orphan Drug Designation for CMMLTHE COUNTDOWN IS ON FDA grants orphan drug designation to onvansertib for relapsed or refractory CMML, boosting development of the PLK1 inhibitor after early signals of activity. Onvansertib has received orphan drug designation from the US…
Related markets
All fda & drugs ›When will the FDA approve Compass Pathways' COMP360 Psilocybin? (COMP360 Psilocybin for Treatment-Resistant Depression)
88%Before 2028
- Before 202888%
- Before July 202785%
- Before October 202785%▲ 1
2 more
- Before Mar 1, 202761%▼ 1
- Before Jan 1, 202728%▲ 5
When will the FDA reclassify BPC-157 to Category 1?
21%Before 2027
- Before 202721%▼ 6
- Before November7%▲ 1
Will the FDA approve retatrutide? (retatrutide (LY3437943))
Oct 22, 2027even chance by
- Before Jan 1, 20274%
- Before Jul 1, 202718%
- Before Jan 1, 202871%
2 more
- Before Jul 1, 202885%
- Before Jan 1, 202990%
FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (in 2026)
92%chance▲ 1
Will the FDA approve any psychedelic substance for medical use this year? (Before 2027)
16%chance
Odds are traders' prices on Kalshi, Polymarket, ForecastEx and Crypto.com, not forecasts by 4Search. Prices read from the venues just now. Prices may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts. Not betting or investment advice.
Prediction-market prices are what traders pay for each outcome on Kalshi, Polymarket, ForecastEx and Crypto.com, read as the market's implied chance. They are not forecasts by 4Search, can move fast and can be wrong; they are read every few minutes and may be delayed. Money traded on Kalshi and ForecastEx is estimated from contracts at their price. News comes from the 4Search index; prices of stocks, rates and coins from 4Search Finance. Nothing here is betting, financial or investment advice. Terms of use.